Abstract Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs in the context of new cancer therapies. Roscovitine and related compounds, like seliciclib and olomoucine, are effective inducers of apoptosis in many proliferating cells in culture. These compounds are known to activate the intrinsic or mitochondrial pathway of apoptosis. In order to better characterize this intrinsic pathway, a transcriptional analysis was performed using the reverse transcriptase-multiplex ligation-dependent probe amplification procedure (RT-MLPA). In five cell lines, we detected an early and marked reduction of most transcripts, which is consistent with the disruption of transcription that results from the inhibition of CDK7 and CDK9. However, the mRNA of p53-upregulated modulator of apoptosis (PUMA) gene escaped from this transcription inhibition in neuroblastoma cells with a functional p53 protein. The increase of PUMA mRNA was not found in roscovitine-treated cell lines defective in p53, which underwent apoptosis like their p53 proficient counterparts. In addition, in SH-SY5Y cells, sublethal and lethal concentrations of roscovitine produced equivalent increases of PUMA mRNA and protein.
Introduction
The 2,6,9-trisubstituted purine chemistry defines a family of drugs characterized by being inhibitors of cyclindependent kinase (CDK) [1] . Roscovitine is the most extensively investigated compound in the family. For instance, only in year 2010, roscovitine has been studied in 79 original publications (reviews excluded), as revealed by means of a PubMed search. The pharmacology of roscovitine focused on cancer application has been recently reviewed in detail [2] . Furthermore, seliciclib, the (R) enantiomer of roscovitine is in clinical phases of development for cancer treatment [3, 4] . These facts notwithstanding, new roscovitine derivatives continue to be sought in order to improve the pharmacological profile of roscovitine [5, 6] . Olomoucine is also a 2,6,9-trisubstituted purine [1] . Olomoucine displays lower pharmacological potency than roscovitine but a similar, though not identical, activity profile [7] . Interestingly, olomoucine has an inactive isomer, named iso-olomoucine that becomes the ideal negative control for biological experiments [8, 9] .
In addition to cancer, other diseases such as retroviral infections, protozoal parasitosis, proliferative glomerulonephritis or several types of neurodegeneration have been regarded as possible applications for roscovitine [1] . Moreover, by apoptosis induction in neutrophils, roscovitine potential as an anti-inflammatory drug is being investigated [10] . In this therapeutic context, roscovitine is known to act paradoxically. Roscovitine triggers apoptosis in many tumor cells [2] but prevents it in other experimental paradigms [11, 12] . A satisfactory explanation for these opposing results is lacking, but a proposal to conciliate them will be further discussed.
We have focused our research on the apoptotic mode of action of roscovitine and olomoucine. Initially, we characterized their effects on SH-SY5Y, a tumor cell line derived from human neuroblastoma. We characterized the time course and concentration dependency of the process [9] . In SH-SY5Y cells, we discarded the involvement of an extrinsic pathway [13] . Furthermore, we showed these drugs to activate BAX protein and to trigger a mitochondrial or intrinsic pathway [14] . Intriguingly, enforced expression of BCL-2 and BCL-X L proteins in SH-SY5Y cells had provided no apoptotic protection against roscovitine and olomoucine [9] . The neutralization of BCL-2 and BCL-X L antiapoptotic effects by this type of compounds remained to be explained in our cell model. In order to investigate this issue, we decided to characterize the gene expression of several regulators of the intrinsic pathway. The RT-MLPA technique was chosen as our analytical tool. This procedure allowed the simultaneous quantification of the mRNA expressed from several genes involved in apoptosis execution and regulation [15, 16] . Our approach revealed that the expression of one p53-regulated gene, PUMA, increased while the others in the test were repressed by the action of roscovitine and related compounds. The translation into protein of the most significant mRNA variations was assessed and agreed in most instances. Taking together our results, we envisage a complex scenario where the balance of some elements integrating the intrinsic pathway, particularly NOXA and MCL-1, are determining if apoptosis will occur.
Materials and methods

Chemical reagents and primary antibodies
Roscovitine, olomoucine, iso-olomoucin, pifithrin-a (Pft-a) and cyclic pifithrin-a (cPft-a) were acquired from Calbiochem (San Diego, CA, USA). Seliciclib (R-roscovitine or CYC202) was kindly supplied by Prof. L. Meijer (Station Biologique de Roscoff, CNRS, France). Anti-BCL-2 monoclonal antibody (Dakocytomation, Glostrup, Denmark) was used at a dilution 1:1000. Anti-BCL-X L polyclonal antibody (BD-Biosciences, San Diego, CA, USA) was employed at a dilution 1:2000. The working dilution for anti-MCL-1 polyclonal antibody from Sigma (St. Louis, MO, USA) and anti-p53 monoclonal antibody from Upstate (Lake Placid, NY, USA) was 1:4000. Analogously, 1:500 was used for anti-NOXA monoclonal antibody (Abcam, Cambridge, UK) and 1:1000 for anti-PUMA polyclonal antibody (Cell Signaling Technologies, Danvers, MA, USA). Glyceraldehyde-3-P-dehydrogenase (GAPDH) was detected directly with a peroxidase-conjugated monoclonal antibody from Sigma. This monoclonal antibody was employed at 1:40000 and its purpose was to assess the protein load per lane in Western blots and densitometry quantifications. Unless otherwise stated, the nonlisted reagents were from Sigma.
Cell culture and drug treatments SH-SY5Y, Jurkat and HL-60 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). IMR-5 and IMR-32 are two cell lines derived from human neuroblastoma, which origin and characterization have been reported before [17, 18] . The cell lines derived from neuroblastoma were grown in 2 mM L-glutamine supplemented DMEM media (Invitrogen, Barcelona, Spain) plus a 10% volume of FCS (Invitrogen). HL-60 and Jurkat cell lines were grown in RPMI media (Invitrogen) plus a 10% volume of FCS. All media contained Plasmocin TM (InvivoGen, San Diego, CA, USA) as the only antibiotic and its concentration was 5 lg/ml. General culturing conditions were 37°C and a water-saturated, 5% CO 2 atmosphere. Stock solutions of roscovitine and the other chemical reagents were prepared in DMSO. From these stock solutions, drugs were delivered to the culture media and adjusted to the final concentrations reported in the text and figures. The serial dilution procedure was used in concentration-dependency determinations.
Cell death and apoptosis assessment
In order to quantify the ratios of cell death in the culture plates, the Cell Titer 96 Ò and Cytotox 96 Ò kits were used. Cell Titer 96 Ò allowed to assess the reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS). Cytotox 96 Ò measured the amount of lactate deshydrogenase (LDH) released from dying cells. Both kits were provided by Promega Biotech Ibérica, SL (Barcelona, Spain) and used as we have previously reported [9] . Alternatively, Trypan blue staining and microscopic counts were also performed. Apoptosis was assessed by two procedures, bisBenzimide/Hoechst 33342 staining of chromatin plus fluorescence microscopy and the activation of DEVD targeted caspases [13] .
RT-MLPA analysis Cultured cells, either treated or untreated, were first washed with PBS and total RNA was extracted from the pellets. For this purpose, the RNeasy Ò kit was used according to the supplier instructions (Qiagen Inc, Valencia, CA, USA). Total RNA concentration was determined in a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and its integrity checked by a standard electrophoresis in agarose gels. Then, RNA samples were subjected to reverse transcriptase multiplex ligationdependent probe amplification (RT-MLPA). The SALSA MLPA kit R011-Apoptosis-mRNA from MRC-Holland (Amsterdam, The Netherlands) was used. This procedure allows the simultaneous detection of 37 mRNA molecules, including the probes for mRNAs of 32 apoptosis-related proteins. In brief, a gene-specific probe mix was used to reverse transcribe 200 ng of total RNA. The resulting cDNA was annealed overnight at 60°C to the MLPA probe mix. Annealed oligonucleotides were ligated by adding Ligase-65 (MRC-Holland, Amsterdam) and incubation at 54°C for 15 min. Ligation products were amplified by PCR (35 cycles, 30 s at 95°C; 30 s at 60°C, and 1 min at 72°C) with one unlabeled and one fluorescence labeled primer. The amplified PCR fragments were separated by capillary electrophoresis on a 48-capillary ABI-Prism 3730 Genetic Analyzer from Applied Biosystems/Hitachi (Foster City, CA, USA). Peak area was measured using GeneScan analysis software (Applied Biosystems). The levels of mRNA for each gene were expressed as a normalized ratio of the peak area divided by the peak area of an internal standard, a housekeeping gene of reference. Precisely, b2-microglobulin for SH-SY5Y and b-glucuronidase for Jurkat, HL60, IMR-5 and IMR-32 cells. Therefore, the relative mRNA content of the genes of interest was calculated as a percentage (see Supplementary Figs. 1, 3, 4) . In several diagrams (Figs. 1, 2, 3, 4) , the base-2 logarithm of the fold induction relative to untreated cells was calculated. This equalized to zero the mRNA content of the untreated conditions.
Western blot analysis
Cultured cells, either treated or untreated, were washed with PBS and proteins extracted from the pellets by a brief sonication in a buffer containing 100 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM PMSF, 2 lg/ml aprotinin, 1 lg/ml leupeptin and 2% SDS. After boiling for 5 min and a centrifugation at 12000 g for 15 min, supernatants were collected and their protein content assessed by the NanoDrop spectrophotometer, mentioned above. Equal amounts of protein were loaded per lane in SDS 10, 12 or 15% polyacrylamide gel electrophoresis depending on the protein subjected to analysis. Then, proteins were transferred to Immobilon-P TM membranes (Millipore Iberica, Madrid, Spain) by means of a MINI Ò trans-blot module from Bio-Rad (Hercules, CA, USA). Membranes were reacted with the primary antibodies described above. Immunoblots were finally developed with the appropriate peroxidase-conjugated secondary antibody from Sigma and Immobilon TM Western detection reagent from Millipore. Chemiluminiscence was recorded and densitometries performed by means of a Chemidoc TM XRS system and the Quantity One (version 4.6) software from Bio-Rad. Peak intensity from each band of interest was normalized by the peak intensity of GAPDH in the same lane and then referred to analogous values from untreated cells. Data were finally translated into base-2 logarithms in order to homogenize these diagrams with those of the RT-MLPA analysis. As in those diagrams, values from the untreated condition became equalized to zero and, therefore, the bars representing the control value disappeared from the graph.
Results
Effects of roscovitine and related compounds on the expression of apoptotic regulators in cell lines derived from neuroblastoma
The main purpose of this report was to characterize the expression of genes regulating apoptosis in our experimental paradigms by means of the RT-MLPA procedure. Unless otherwise stated, SH-SY5Y cells were treated with 50 lM roscovitine. We have determined this to be the standard concentration to induce apoptosis in most of the cell population at 48 h of treatment [9] . Total RNA was extracted after 6 h of treatment, a time characterized by a minimal activation of effector caspases (DEVDase activity) and extensive integrity of the cells [9, 13] . In order to check the effect of the drugs, control cultures were run in parallel and cell death was tested after 48 h of treatment. At this time trypan blue and LDH release procedures confirmed that death was occurring in most of the cell population, as expected. The extracted RNA was then subjected to RT-MLPA analysis. Data were plotted into two types of bar diagrams ( Fig. 1, supplementary Fig. 1 ). In Fig. 1 , bar value is the fold mRNA content has changed in treated versus untreated cells and, the number, is expressed as a base-2 logarithm (log 2 ). This type of graph type of graph notwithstanding, similar conclusions could be drawn: a marked reduction for most of the mRNA studied. However, one exception emerged. Roscovitine treatment was increasing the mRNA of the BH3-only protein PUMA, on average, 4 times. Next we tested other compounds related to roscovitine, precisely olomoucine and seliciclib in one experiment. At the concentrations employed, these compounds induce ratios and kinetics of cell apoptosis equivalent to those of roscovitine [9, 19] . RT-MLPA analysis was performed and controlled as described before. The results were analogous to those previously obtained with roscovitine as these compounds caused a general decrease of most mRNAs and an increase of PUMA that averaged fourfolds (Fig. 2a) . In the same experiment, iso-olomoucine was tested (white bars in Fig. 2a ). As expected, the profile generated by iso-olomoucine differed little from the one of untreated SH-SY5Y cells. Iso-olomoucine does not inhibit CDK at this concentration, does not cause cell death and becomes a good negative control of the experiment. Iso-olomoucine could have identified offtarget effects of the 2,6,9-trisubstituted purines on the expression of the genes studied by the RT-MLPA procedure.
In order to generalize these data to other cell lines, in one experiment we tested the effect of roscovitine on IMR-5 and IMR-32. Both cell lines are derived from human neuroblastoma. In these cell lines, we had previously studied the apoptotic effect of roscovitine and found to occur within a range of concentrations analogous to the one reported for SH-SY5Y [19] . Therefore, IMR-5 and IMR-32 cells were subjected to a treatment with 50 lM roscovitine for 6 h. Cell death and RNA integrity were checked and, finally, RT-MLPA analysis was performed (Fig. 2b) . The results displayed a great homology to those previously found in SH-SY5Y cells. PUMA is a BH3-only protein and its mRNA transcription is regulated by p53 [20, 21] . Neuroblastoma is a type of tumor characterized by maintaining a functional p53 protein, as we have observed in the three cell lines mentioned above [19] . Consequently, we questioned the involvement of p53 in the increase of PUMA mRNA caused by roscovitine. To first approach this issue, we thought of performing RT-MLPA analyses in cell lines known for being defective in p53. We chose HL-60 and Jurkat cell lines [22, 23] . HL-60 cells are derived from human promyelocytic leukemia and Jurkat cells, from human T cell leukemia. Since we had no previous characterization of the effects of roscovitine on these cell lines, we proceeded to characterize the concentration dependency of cell death by the MTS reduction (Fig. 3a) and the LDH release procedure (Fig. 3b) . The range of death inducing concentrations did not differ from the one observed in the neuroblastoma cell lines. In addition, the type of cell death was characterized and found to be apoptotic based on the activation of effector caspases (Fig. 3c ) and the nuclear morphology after bisBenzimide staining of chromatin ( Supplementary  Fig. 2 ). Finally, in one experiment, HL-60 ( Supplementary  Fig. 3 ) and Jurkat cells ( Supplementary Fig. 4 ) were treated with roscovitine (50 lM) for 6 h and the RT-MLPA analysis was performed. Again, a marked reduction in the content of most mRNAs was detected (Fig. 3d) . Interestingly, roscovitine did not cause PUMA mRNA increase in these cell lines defective in p53. In conclusion, neither p53 nor PUMA mRNA increase were necessary for apoptosis to occur in these cell lines.
To further explore this issue, in one experiment, we decided to use Pft-a and cPft-a. Both compounds are known for their ability to inhibit the transcriptional activity of p53 [24] . In SH-SY5Y cells, both compounds had a negligible effect on PUMA mRNA when used alone. However, both reversed the increase of PUMA mRNA caused by roscovitine in these cells. Moreover, we observed the mRNA to decrease (Fig. 4a) , as previously observed in the HL-60 and Jurkat cell lines (Fig. 3d) . Next we tested if Pft-a and cPft-a had any effect on the death ratios caused by roscovitine in SH-SY5Y cells. We found neither compound modified the death ratios (Fig. 4b) . In conclusion, the increase of PUMA mRNA was an event that was being sustained by the transcriptional activity of p53 in SH-SY5Y cells treated with roscovitine. Furthermore, the increase of PUMA mRNA was not an event necessary for roscovitine to trigger apoptosis in these cells.
A prominent reduction in MCL-1 expression correlated with apoptosis induction by roscovitine
In our previous studies, we had determined 10 lM to be a sublethal concentration for roscovitine after 48 h of treatment [9, 19] . We wondered what the RT-MLPA comparison of a sublethal versus a lethal concentration of roscovitine could uncover. Therefore, in one experiment, SH-SY5Y cells were treated for 6 h with roscovitine at sublethal (10 lM) or lethal (50 lM) concentrations and RT-MLPA was performed (Fig. 4c) . Surprisingly, the RT-MLPA profile was quite similar when the sublethal and lethal conditions were compared. Most mRNAs were reduced in the sublethal condition. Therefore, the roscovitine-induced disruption of transcription was already detectable at a concentration 10 lM. Similarly, the increase of PUMA mRNA was also observed in the sublethal paradigm. This fact reinforced previous evidences about a non-essential role for the increase of PUMA mRNA in the cell death process. The only significant differences were observed in the mRNA content of the BCL-2-like genes. Lethal concentrations of roscovitine caused a greater reduction of BCL-2, BCL-W, BCL-X L and MCL-1 mRNAs than sublethal ones. The most manifest decay was observed in the content of MCL-1 mRNA. This event correlated the best with apoptosis induction triggered by roscovitine in SH-SY5Y cells.
Protein content modifications associated with the roscovitine treatment
Since the mRNA content does not necessarily correlate with the protein one, we decided to validate some of the RT-MLPA results by Western blot (Supplementary Fig. 5 ), densitometric analysis and quantification, as reported in the methods section. In addition we used a time course approach to better characterize the phenomena. Initially, we focused on p53 protein and two of their downstream regulated targets, the BH-3-only proteins NOXA and PUMA (Fig. 5) . Lethal concentrations stabilized p53 protein to a greater extent or, alternatively, with a faster kinetics than sublethal ones. NOXA is a BH3-only protein that preferentially binds and becomes neutralized by MCL-1 [25] . Accordingly, it was a good candidate to participate in the mechanism of apoptosis triggered by Roscovitine. NOXA mRNA experienced a small increase in the sublethal condition and a clear decrease in the lethal one (Fig. 4c) . NOXA protein mimicked the behavior of the mRNA and, consequently, no clear correlation with cell death could be initially established. Concerning PUMA protein, four isoforms (a, b, c and d) are possible and known to be the consequence of differential splicing [21] . However, only a and b isoforms are truly BH3-only proteins, displaying one BH3 domain and being involved in triggering the intrinsic pathway of apoptosis. Let us comment that RT-MLPA does not distinguish between the mRNAs coding for a and b isoforms and quantifies them together. To better understand the role of PUMA in our experimental paradigm, we distinguished both isoforms in the Western blot. We employed an anti-PUMA polyclonal antibody able to recognize one band at 23-24 kDa (PUMA a) and another one at 16-18 kDa (PUMA b). The kinetic profile for PUMA a increase reproduced the profile of p53 stabilization, either at sublethal or at lethal concentrations of roscovitine (Fig. 5) . The kinetic profile for PUMA b only reproduced the one of p53 in the sublethal treatment. At lethal concentrations of roscovitine, PUMA b displayed a tendency to decrease in a quite variable way (Fig. 5) . Taken together these results agreed with our previous ones connecting p53 activation by roscovitine and the rise of PUMA mRNA. Moreover, we realized that the sum of PUMA a and b isoforms in the sublethal paradigm surpassed the sum in the lethal one. This provides an additional argumentation to support the lack of correlation between roscovitine-induced apoptosis and the increment of PUMA mRNA or PUMA a protein.
Finally, we focused on MCL-1, BCL-2 and BCL-X L proteins (Fig. 6 ). BCL-2 and BCL-X L protein content underwent decreases, but no clear difference emerged when sublethal and lethal conditions were compared. On the other hand, MCL-1 behaved quite differently. MCL-1 protein content increased at sublethal roscovitine concentrations and dramatically decreased at lethal ones. Consequently, the RT-MLPA results suggesting the depletion of MCL-1 as the best correlation for apoptosis induction seemed to be confirmed. If not discarded, the role for BCL-2 and BCL-X L reduction in apoptosis induction seemed, at best, accessory. 
Discussion
The experiments reported herein show that the cellular content of most mRNAs decay at 6 h following a treatment with CDK inhibitory drugs, a time characterized by a minimal activity of effector caspases and, therefore, no loss of cell and mRNA integrity. This fact is consistent with the reported inhibition of CDK7 and CDK9 by this type of compounds [2, 26] . Respectively, CDK7 and CDK9 are essential elements in regulating transcription initiation and elongation by RNA polymerase II [26] . In other words, roscovitine and their analogues cause an early and marked reduction in the cellular content of mRNAs due to a specific type of transcription inhibition. However, some genes are able to escape from this repression scenario. Precisely, we have found the PUMA mRNA to do so. PUMA is the acronym of p53-upregulated modulator of apoptosis. Accordingly, we have demonstrated this increase to be a transcriptional event mediated by p53. In addition, we have shown the mRNA increase to translate into increases of both, PUMA a and b proteins. Other p53-regulated genes can probably behave like PUMA. For instance, p21 protein is known to accumulate upon roscovitine treatment of SH-SY5Y cells [19] . The induction of PUMA and reduction of MCL-1 expression are found in leukemic cells overexpressing protein p16 INK4A , a physiological inhibitor of CDK [27] . Moreover, our results closely mimic those reported for DRB (5,6-di-chloro-1-b-D-ribofuranosyl-benzimidazole), the most accepted chemical inhibitor of transcription elongation. Like roscovitine, DRB elicits p53 activation and promotes the expression of p21 and PUMA genes in a context of broad transcription inhibition [28] . These opposing effects on transcription provide a good explanation for a paradoxical issue, the fact that roscovitine displays the ability to either induce [2] or prevent apoptosis [11, 12] . The roscovitine-induced modulation of the balance between apoptotic and antiapoptotic proteins provides a good explanation for it. If one protein required for apoptosis to occur is down-regulated, roscovitine will prevent apoptosis. On the contrary, apoptosis will take place if the down-regulated protein is antiapoptotic and necessary to keep a primed apoptosis in check. The molecular mechanisms explaining why some p53-regulated genes circumvent the disruption of transcription elongation by RNA polymerase II remain unclear and, in our opinion, deserve future investigations. Particularly, since these mechanisms seem to define a p53-mediated safeguard present in the cells to confront dysfunction in the process of transcription elongation.
On the other hand, we have shown that the up-regulation of PUMA is not a necessary event for roscovitine to induce apoptosis. We believe that the evidences obtained make unproductive additional experiments approaching this issue. Other events must happen and become more pivotal in the cell death process. For example, the marked reduction detected in the antiapoptotic MCL-1 protein. This result was not unexpected since it is the most agreed event in the mode of apoptosis induction by roscovitine [29] [30] [31] . However, some issues remained to be explained. Based on the existing knowledge, MCL-1 is expected to act by neutralizing one or several BH3-only proteins [25] . The question was which ones were being released following the MCL-1 decay and became the activators of apoptosis. Initially, PUMA protein was a good candidate. However, as stated before, our results concluded its role to be nonessential or, at best, supplementary. We knew that the overexpression of functional BCL-2 and BCL-X L proteins do not protect SH-SY5Y cells from roscovitine [9] . Therefore, the BH-3 protein candidate should circumvent the neutralization of BCL-2 and BCL-X L neutralization but not the one of MCL-1. This reasoning attracted our attention on NOXA, a BH3-only protein characterized by its specificity for MCL-1 interaction. Disappointingly, the RT-MLPA analyses were not informative since NOXA and MCL-1 mRNA were found to decrease. Interestingly, when the protein content was characterized, we realized that NOXA did not decrease to the same extent than MCL-1. If Fig. 5 and 6 are compared, after 9-12 h of roscovitine treatment, we will see MCL-1 has reduced its content eight times while NOXA has decreased, at best, one half. We propose this unbalance to be a decisive event in the mode of apoptosis induction by roscovitine. An analogous conclusion has been obtained in our previous reports about the apoptotic mode of action of NSAID (non-steroidal antiinflammatory drugs) and Akt inhibitory compounds [32, 33] . Moreover, NOXA downregulation by RNA interference conferred a significant protection to hematological cell lines treated with seliciclib [34] . The decrease of MCL-1 protein is characteristic of apoptotic models caused by the inhibition of new protein synthesis [35] [36] [37] . The MCL-1 decay is the expected consequence of the proteosome avidity for MCL-1 digestion, which determines the elevated turnover of this protein. Consequently, the cellular MCL-1 content is a sensitive marker of the disruption of the transcriptional or translational machinery and the MCL-1/NOXA balance becomes the ideal rheostat to connect this dysfunction to apoptosis. While this report was in the reviewing process, NOXA was reported to be a substrate of CDK5. Upon phosphorylation by CDK5 at serine 13, NOXA is sequestered in a cytosolic macromolecular complex and, as a consequence, its proapoptotic function at mitochondria is neutralized. [38] . In other words, not only the protein content of NOXA has to be taken into account but its phosphorylation state too. Roscovitine is a potent inhibitor of CDK5. Therefore, in our paradigm, NOXA will be hypophosphorylated. This means that the functional MCL-1/NOXA imbalance will be far greater than we suspected.
Finally, the just mentioned report introduces a new point to be discussed [38] . Which CDK entities have a relevant role in the apoptotic mode of action of Roscovitine? Roscovitine inhibits CDK1, 2, 5, 7 and 9 but not the other CDK [1] . Other kinases like ERK and pyridoxal kinase are inhibited by Roscovitine, but their involvement in our models has been discarded [9, 39] . It is now evident that the interplay of CDK5, CDK7 and CDK9 is crucial in establishing the ratio MCL-1/hypophosphorylated NOXA, the actual rheostat that will determine if apoptosis will occur. The role of CDK2 inhibition seems to be at best accessory, since cells defective in CDK2 display only a negligible death resistance when treated with roscovitine [39] . Only the role of CDK1 in the apoptotic mode of action of roscovitine remains to be ascertained. Since cells defective in CDK1 are not viable, a cellular model is lacking to address this issue.
